Contact Congress about S. 2617: Reducing Drug Prices for Seniors Act.

Some Medicare drug plans would have to base coinsurance on a drug's lower net price instead of its higher list price. That could lower what some seniors pay at the pharmacy. The rule starts in 2026 for certain Part D drug costs.

Modern Action explains what the legislation does, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Reducing Drug Prices for Seniors Act. is a Senate bill in committee. The latest recorded action: Read twice and referred to the Committee on Finance.

Latest action on S. 2617: Read twice and referred to the Committee on Finance.

Who this affects: This bill mainly affects seniors and other Medicare patients who are in Part D or Medicare Advantage drug plans and pay coinsurance for prescriptions. It matters most for people whose drugs have rebates or discounts that make the net price lower than the list price. Drug plans would have to change how they calculate those patient charges. Drug makers could also feel indirect effects if plans respond differently in rebate negotiations.

Why this matters: Some seniors now pay coinsurance based on a drug's higher list price even when their plan gets rebates or discounts that lower the real cost. This bill would tie those patient charges more closely to the lower net price. That could reduce what some people pay out of pocket during the year. The exact savings would vary by plan, by drug, and by how large the hidden discounts are. The bill could also affect how plans and drug makers bargain over rebates, but it does not say how those business deals should change.

Key provisions in S. 2617

• This applies to Medicare Part D plans and Medicare Advantage drug plans that use coinsurance for covered drugs. It covers drugs on the plan's formulary, which is its covered-drug list.
• Patients would pay coinsurance based on the drug's lower net price when that is below the list price. This rule applies after the deductible and before the standard out-of-pocket limit.
• The bill sets net price as the negotiated price minus manufacturer rebates and other discounts. It uses figures reported in the Detailed DIR Report, or a replacement report, from the prior plan year.
• Not every drug is covered by this change. It leaves out certain drugs that existing Medicare law already handles in two special categories.
• The new rule starts with plan years that begin on or after January 1, 2026. It would not apply earlier than that.

How Modern Action helps you take action on S. 2617

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about S. 2617

What is S. 2617?

Some Medicare drug plans would have to base coinsurance on a drug's lower net price instead of its higher list price. That could lower what some seniors pay at the pharmacy. The rule starts in 2026 for certain Part D drug costs.

How do I support or oppose S. 2617?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about S. 2617?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

How does Modern Action help me act on S. 2617?

Modern Action gives you bill-specific context, lets you choose support, opposition, or changes, and drafts a message from your position and reasons.